AMINOSYN II 8.5% W/ELECTROLYTES
LOE Approachingamino acids; magnesium chloride; potassium chloride; sodium chloride; sodium phosphate, dibasic
NDAINJECTIONINJECTABLE
Approved
Apr 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMINOSYN II 8.5% W/ELECTROLYTES is an intravenous amino acid formulation with essential electrolytes designed for parenteral nutrition support in hospitalized patients. It provides balanced essential and non-essential amino acids along with magnesium, potassium, sodium, and phosphate to maintain nitrogen balance and electrolyte homeostasis. This product is indicated for patients who cannot receive adequate nutrition through oral or enteral routes.
LOE Approaching
As an established parenteral nutrition product approaching loss of exclusivity, the brand team is likely focused on defending market share and managing generic transition rather than driving growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product offers career opportunities in operational excellence, regulatory maintenance, and hospital relationship management rather than innovation or field expansion. Professionals should expect a stable but non-growth environment focused on defending market position and managing transition to loss of exclusivity.
Supply Chain ManagerRegulatory Affairs Specialist
Worked on AMINOSYN II 8.5% W/ELECTROLYTES at ICU Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.